NCT04904120View on ClinicalTrials.gov

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

September 20, 2022

Study Completion Date

September 20, 2022

Conditions
Melanoma (Skin)Melanoma Stage IVMelanoma, UvealMelanoma, Mucosal
Interventions
DRUG

[203Pb]VMT01

Diagnostic imaging radiopharmaceutical; by intravenous infusion

DRUG

[68Ga]VMT02

Diagnostic imaging radiopharmaceutical; by intravenous infusion

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

lead

Perspective Therapeutics

INDUSTRY

NCT04904120 - Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy | Biotech Hunter | Biotech Hunter